High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence
Authors:
Open Access
- 7 October 2024
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (10) , e29899
Abstract
BRAAVE (NCT03631732), a Phase 3b, multicenter, open‐label US study, demonstrated the efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among Black individuals with suppressed HIV through 48 weeks. Here, 72‐week resistance, adherence, and virologic outcomes are presented. Enrollment criteria permitted nonnucleoside reverse transcriptase inhibitor (NNRTI)–resistance (R), protease inhibitor (PI)–R, and certain nucleos(t)ide reverse transcriptase inhibitor (NRTI)–R (M184V/I allowed; ≥3 thymidine analog mutations [TAMs] excluded); but excluded primary integrase strand transfer inhibitor (INSTI)‐R. Pre‐existing resistance was determined using historical genotypes and retrospective baseline proviral DNA genotyping. Adherence, virologic outcomes, and viral blips were assessed. Of 489 participants receiving B/F/TAF with ≥1 post‐switch HIV‐1 RNA measurement: pre‐existing NRTI‐R (15% of participants), M184V/I (11%), ≥1 TAMs (8%), NNRTI‐R (22%), and PI‐R (13%) were observed; pre‐existing INSTI‐R substitutions (2%) were detected post‐randomization; mean viral blip frequency was 0.9% across all timepoints (unassociated with virologic failure); 24% of participants had <95% adherence (98% of whom had HIV‐1 RNA <50 copies/mL at last visit); none had treatment‐emergent study‐drug resistance. Overall, 99% of participants, including all with baseline NRTI‐R/INSTI‐R, had HIV‐1 RNA <50 copies/mL at the last visit, demonstrating that B/F/TAF maintained virologic suppression through 72 weeks regardless of pre‐existing resistance, viral blips, and suboptimal adherence.Keywords
This publication has 23 references indexed in Scilit:
- Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialseClinicalMedicine, 2023
- Antiviral activity of tenofovir alafenamide (TAF) against HIV‐1 clinical isolates harboring K65RJournal of Medical Virology, 2023
- Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label TrialInfectious Diseases and Therapy, 2021
- Exploring the Engagement of Racial and Ethnic Minorities in HIV Treatment and Vaccine Clinical Trials: A Scoping Review of Literature and Implications for Future ResearchAIDS Patient Care and STDs, 2020
- Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemicJournal of Virus Eradication, 2020
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialThe Lancet HIV, 2018
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trialThe Lancet HIV, 2018
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialThe Lancet, 2017
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialThe Lancet, 2017
- Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical IsolatesThe Journal of Infectious Diseases, 2003